Literature DB >> 12869656

Prevalence of necrosis in C2-ceramide-induced cytotoxicity in NB16 neuroblastoma cells.

Belen Ramos1, Jill M Lahti, Enrique Claro, Suzanne Jackowski.   

Abstract

The mechanism of cell death triggered by C2-ceramide was investigated using the NB16 neuroblastoma cell line. Treatment of NB16 cells with 20 microM C2-ceramide for 20 h resulted in approximately 75% loss of cell viability, but only 25% of cells were scored as apoptotic based on terminal deoxynucleotidyl transferase nick-end labeling. Ultrastructural analysis revealed early development of necrotic cytoplasmic vacuolization. After 20 h of treatment with C2-ceramide, the majority of cells possessed necrotic morphology with pronounced cytoplasmic vacuolization and without any nuclear changes, although a quarter of the cell population also exhibited clear perinuclear chromatin condensation characteristic of apoptosis. Flow cytometric analysis of cells labeled with both annexin V and propidium iodide showed the rapid accumulation of C2-ceramide-treated cells in the necrotic/late apoptotic fraction. In contrast, cells treated with tumor necrosis factor alpha plus cycloheximide (TNFalpha + CHX) first appeared in the early apoptotic fraction and then accumulated in the necrotic/late apoptotic fraction. Both C2-ceramide and TNFalpha + CHX increased caspase 8- and 3-like activities in cytosolic extracts; however, treatment of cells with the broad-spectrum caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone protected NB16 cells from TNFalpha + CHX-induced cell death but did not prevent C2-ceramide cytotoxicity. Although C2-ceramide triggered apoptosis in a fraction of the cells, cell death in the population was primarily caused by necrosis. Thus, C2-ceramide does not faithfully mimic the effects of apoptotic ligands such as TNFalpha, which are thought to be mediated by an accumulation of endogenous ceramide. The inhibition of phosphatidylcholine synthesis is a target for C2-ceramide-mediated cytotoxicity, and this work suggests that other agents that kill cells by inhibiting this pathway may also use a mixture of mechanisms, including necrosis as well as apoptosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869656     DOI: 10.1124/mol.64.2.502

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione.

Authors:  Francisco Caballero; Anna Fernández; Nuria Matías; Laura Martínez; Raquel Fucho; Montserrat Elena; Joan Caballeria; Albert Morales; José C Fernández-Checa; Carmen García-Ruiz
Journal:  J Biol Chem       Date:  2010-04-15       Impact factor: 5.157

Review 2.  Tumor necrosis factor-mediated cell death: to break or to burst, that's the question.

Authors:  Franky Van Herreweghe; Nele Festjens; Wim Declercq; Peter Vandenabeele
Journal:  Cell Mol Life Sci       Date:  2010-03-04       Impact factor: 9.261

3.  Effects of hypoxia, glucose deprivation and acidosis on phosphatidylcholine synthesis in HL-1 cardiomyocytes. CTP:phosphocholine cytidylyltransferase activity correlates with sarcolemmal disruption.

Authors:  Elisabet Sarri; David Garcia-Dorado; Arancha Abellan; Jordi Soler-Soler
Journal:  Biochem J       Date:  2006-02-15       Impact factor: 3.857

4.  Evidence for ceramide induced cytotoxicity in retinal ganglion cells.

Authors:  Jie Fan; Jiali Liu; Jian Liu; Chunhe Chen; Yiannis Koutalos; Craig E Crosson
Journal:  Exp Eye Res       Date:  2021-09-07       Impact factor: 3.770

5.  Dietary glucosylceramides suppress tumor growth in a mouse xenograft model of head and neck squamous cell carcinoma by the inhibition of angiogenesis through an increase in ceramide.

Authors:  Hiroaki Yazama; Kazuyuki Kitatani; Kazunori Fujiwara; Misaki Kato; Mayumi Hashimoto-Nishimura; Katsuyuki Kawamoto; Kensaku Hasegawa; Hiroya Kitano; Alicja Bielawska; Jacek Bielawski; Toshiro Okazaki
Journal:  Int J Clin Oncol       Date:  2014-08-01       Impact factor: 3.402

6.  Calcium and mitochondrial metabolism in ceramide-induced cardiomyocyte death.

Authors:  Valentina Parra; Francisco Moraga; Jovan Kuzmicic; Camila López-Crisosto; Rodrigo Troncoso; Natalia Torrealba; Alfredo Criollo; Jessica Díaz-Elizondo; Beverly A Rothermel; Andrew F G Quest; Sergio Lavandero
Journal:  Biochim Biophys Acta       Date:  2013-04-16

7.  ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.

Authors:  Raquel Fucho; Laura Martínez; Anna Baulies; Sandra Torres; Nuria Tarrats; Anna Fernandez; Vicente Ribas; Alma M Astudillo; Jesús Balsinde; Pablo Garcia-Rovés; Montserrat Elena; Ina Bergheim; Sophie Lotersztajn; Christian Trautwein; Hanna Appelqvist; Adrienne W Paton; James C Paton; Mark J Czaja; Neil Kaplowitz; Jose C Fernandez-Checa; Carmen García-Ruiz
Journal:  J Hepatol       Date:  2014-06-16       Impact factor: 25.083

8.  Bacterial inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain.

Authors:  Janine Zweigner; Suzanne Jackowski; Shannon H Smith; Marie Van Der Merwe; Joerg R Weber; Elaine I Tuomanen
Journal:  J Exp Med       Date:  2004-07-05       Impact factor: 14.307

9.  C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia.

Authors:  Lindsay K Ryland; Ushma A Doshi; Sriram S Shanmugavelandy; Todd E Fox; Cesar Aliaga; Kathleen Broeg; Kendall Thomas Baab; Megan Young; Osman Khan; Jeremy K Haakenson; Nancy Ruth Jarbadan; Jason Liao; Hong-Gang Wang; David J Feith; Thomas P Loughran; Xin Liu; Mark Kester
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

10.  The pentachlorophenol metabolite tetrachlorohydroquinone induces massive ROS and prolonged p-ERK expression in splenocytes, leading to inhibition of apoptosis and necrotic cell death.

Authors:  Hsiu-Min Chen; Ben-Zhan Zhu; Rong-Jane Chen; Bour-Jr Wang; Ying-Jan Wang
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.